Hydrogen sulphide induces μ opioid receptor-dependent analgesia in a rodent model of visceral pain

Molecular Pain

Volumn 6, Issue , 2010, Pages

  Distrutti, Eleonora ^a   Cipriani, Sabrina ^b   Renga, Barbara ^b   Mencarelli, Andrea ^b   Migliorati, Marco ^b   Cianetti, Stefano ^b   Fiorucci, Stefano ^b  

^a SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BETA ARRESTIN; DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR ANTAGONIST; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLARGINYLTHREONYLPENICILLAMINYLTHREONINAMIDE 2,7 DISULFIDE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; GLIBENCLAMIDE; HYDROGEN SULFIDE; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR ANTAGONIST; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR ANTAGONIST; PROTEIN KINASE B; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ANALGESIC AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; POTASSIUM CHANNEL; SODIUM SULFIDE; SULFIDE;

ANALGESIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CELL IMMORTALIZATION; COLORECTAL DISEASE; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; ENZYME MECHANISM; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; INTERNALIZATION; MALE; NERVE CELL; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; TRANSACTIVATION; VISCERAL PAIN; WITHDRAWAL REFLEX; ANIMAL; CELL LINE; DISEASE MODEL; DRUG ANTAGONISM; DRUG POTENTIATION; METABOLISM; PAIN; VISCERA; WISTAR RAT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANALGESIA; ANALGESICS; ANIMALS; CELL LINE; DISEASE MODELS, ANIMAL; HUMANS; HYDROGEN SULFIDE; KATP CHANNELS; MALE; PAIN; POTASSIUM CHANNELS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; RECEPTORS, OPIOID, MU; SULFIDES; VISCERA;

EID: 77953310582     PISSN: 17448069     EISSN: None     Source Type: Journal    
DOI: 10.1186/1744-8069-6-36     Document Type: Article

References (55)

1. Fiorucci S, Distrutti E, Cirino G, Wallace JL. The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver. Gastroenterology 2006, 131:259-271. 10.1053/j.gastro.2006.02.033, 16831608.
2. Wang R. Two's company three's a crowd: can H2S be the third endogenous gaseous transmitter?. FASEB J 2002, 16:1792-1798. 10.1096/fj.02-0211hyp, 12409322.
3. Boehning D, Snyder SH. Novel neural modulators. Annu Rev Neurosci 2003, 26:105-131. 10.1146/annurev.neuro.26.041002.131047, 14527267.
4. Schemann M, Grundy D. Role of hydrogen sulfide in visceral nociception. Gut 2009, 58:744-747. 10.1136/gut.2008.167858, 19433593.
5. Zhao W, Zhang J, Lu Y, Wang R. The vasorelaxant effect of H2S as a novel endogenous gaseous KATP channel opener. EMBO J 2001, 20:6008-6016. 10.1093/emboj/20.21.6008, 125693, 11689441.
6. Abe K, Kimura H. The possible role of hydrogen sulfide as an endogenous neuromodulator. J Neurosci 1996, 16:1066-1071.
7. Eto K, Ogasawara M, Umemura K, Nagai Y, Kimura H. Hydrogen sulfide is produced in response to neuronal excitation. J Neurosci 2002, 22:3386-3391.
8. Kimura H. Hydrogen sulfide induces cyclic AMP and modulates the NMDA receptors. Biochem Biophys Res Commun 2000, 267:129-133. 10.1006/bbrc.1999.1915, 10623586.
9. Dello Russo C, Tringali G, Ragazzoni E, Maggiano N, Menini E, Vairano M, Preziosi P, Navarra P. Evidence that hydrogen sulphide can modulate hypothalamo-pituitary-adrenal axis function:in vitro and in vivo studies in the rat. J Neuroendocrinol 2000, 12:225-233. 10.1046/j.1365-2826.2000.00441.x, 10718918.
10. Whiteman M, Armstrong JS, Chu SH, Jia-Ling S, Wong BS, Cheung NS, Halliwell B, Moore PK. The novel neuromodulator hydrogen sulfide: an endogenous peroxynitrite 'scavenger'?. J Neurochem 2004, 90:765-768. 10.1111/j.1471-4159.2004.02617.x, 15255956.
11. Distrutti E, Sediari L, Mencarelli A, Renga B, Orlandi S, Antonelli E, Roviezzo F, Morelli A, Cirino G, Wallace JL, Fiorucci S. Evidence that hydrogen sulfide exerts antinociceptive effects in the gastrointestinal tract by activating KATP channels. J Pharmacol Exp Ther 2006, 316:325-335. 10.1124/jpet.105.091595, 16192316.
12. Distrutti E, Sediari L, Mencarelli A, Renga B, Orlandi S, Russo G, Caliendo G, Santagada V, Cirino G, Wallace JL, Fiorucci S. 5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-12dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine exerts antinociceptive effects in a model of postinflammatory hypersensitivity. J Pharmacol Exp Ther 2006, 319:447-458. 10.1124/jpet.106.106435, 16855178.
13. Uhl GR, Childers S, Pasternak G. An opiate-receptor gene family reunion. Trend Neurosci 1994, 17:89-93. 10.1016/0166-2236(94)90110-4, 7515530.
14. Reisine T, Bell GI. Molecular biology of opioid receptors. Trends Neurosci 1993, 16:506-510. 10.1016/0166-2236(93)90194-Q, 7509520.
15. Sternini C, Brecha NC, Minnis J, D'Agostino G, Balestra B, Fiori E, Tonini M. Role of agonist-dependent receptor internalization in the regulation of μ opioid receptors. Neuroscience 2000, 98:233-241. 10.1016/S0306-4522(00)00118-4, 10854754.
16. Sternini C, Spann M, Anton B, Keith DE, Bunnett NW, von Zastrow M, Evans C, Brecha NC. Agonist-selective endocytosis of μ-opioid receptor by neurons in vivo. Proc Natl Acad Sci 1996, 93:9241-9246. 10.1073/pnas.93.17.9241, 38626, 8799185.
17. Mantyh PW, DeMaster E, Malhotra A, Ghilardi JR, Rogers SD, Mantyh CR, Liu H, Basbaum AI, Vigna SR, Maggio JE. Receptor endocytosis and dendrite reshaping in spinal neurons after somatosensory stimulation. Science 1995, 268:1629-1632. 10.1126/science.7539937, 7539937.
18. Ferguson SS, Zhang J, Barak LS, Caron MG. Role of beta-arrestins in the intracellular trafficking of G-protein-coupled receptors. Adv Pharmacol 1998, 42:420-424. full_text, 9327929.
19. Rodrigues ARA, Duarte IDG. The peripheral antinociceptive effect induced by morphine is associated with ATP-sensitive K + channels. Br J Pharmacol 2000, 129:110-114. 10.1038/sj.bjp.0703038, 1621137, 10694209.
20. Ocaña M, Cendán CM, Cobos EJ, Entrena JM, Baeyens JM. Potassium channels and pain: present realities and future opportunities. Eur J Pharmacol 2004, 500:203-219. 10.1016/j.ejphar.2004.07.026, 15464034.
21. Yong QC, Lee SW, Foo CS, Neo KL, Chen X, Bian JS. Endogenous hydrogen sulphide mediates the cardioprotection induced by ischemic postconditioning. Am J Physiol Hearth Circ Physiol 2008, 295:H1330-H1340.
22. Polakiewicz RD, Schieferl SM, Gingras AC, Sonenberg N, Comb MJ. μ-Opioid receptor activates signalling pathways implicated in cell survival and translational control. J Biol Chem 1998, 273:23534-23541. 10.1074/jbc.273.36.23534, 9722592.
23. Musial F, Crowell MD, Kalveram KT, Enck P. Nutrient ingestion increases rectal sensitivity in humans. Physiol Behav 1994, 55:953-956. 10.1016/0031-9384(94)90085-X, 8022917.
24. Distrutti E, Hauer SK, Fiorucci S, Pensi MO, Morelli A. Intraduodenal lipids increase perception of rectal distension in IBS patients. Gastroenterology 2000, 118(4, suppl 2):A138.
25. Simrén M, Agerforz P, Björnsson ES, Abrahamsson H. Nutrient-dependent enhancement of rectal sensitivity in irritable bowel syndrome (IBS). Neurogastroenterol Motil 2007, 19:20-29.
26. Raynor K, Kong H, Chen Y, Yasuda K, Yu L, Bell GI, Reisine T. Pharmacological characterization of the clones kappa delta and mu opioid receptor. Mol Pharmacol 1994, 45:330-334.
27. Gutstein HB, Akil H. Opioid analgesics. Goodman and Gilman's The pharmacological basis of therapeutics. 2001, 569-619. New York: McGraw-Hill, Hardman JGL, Limbird LE.
28. Danzebrink RM, Green SA, Gebhart GF. Spinal mu and delta but not kappa opioid-receptor agonists attenuate responses to noxious colorectal distension in the rat. Pain 1995, 63:39-47. 10.1016/0304-3959(94)00275-J, 8577489.
29. Marker CL, Lujan R, Loh HH, Wickman K. Spinal G-protein-gated potassium channels contribute in a dose-dependent manner to the analgesic effect of μ- and δ- but not κ-opioids. J Neurosci 2005, 25:3551-3559. 10.1523/JNEUROSCI.4899-04.2005, 15814785.
30. Pacheco DF, Reis GM, Francischi JN, Castro MS, Perez AC, Duarte ID. Delta-opioid receptor agonist SNC80 elicits peripheral antinociception via delta (1) and delta (2) receptors and activation of the l-arginine/nitric oxide/cyclic GMP pathway. Life Sci 2005, 78:54-60. 10.1016/j.lfs.2005.04.032, 16135369.
31. Gendron L, Pintar JE, Chavkin C. Essential role of mu opioids receptor in the regulation of delta opioids receptor-mediated antihyperalgesia. Neurosci 2007, 150:807-817.
32. Bilsky EJ, Wang T, Lai J, Porreca F. Selective blockade of peripheral delta opioids agonist induced antinociception by intrathecal administration of delta receptor antisense oligodeoxynucleotide. Neurosci Lett 1996, 220:155-158. 10.1016/S0304-3940(96)13262-6, 8994216.
33. Fraser GL, Pradhan AA, Clarke PB, Wahlestedt C. Supraspinal antinociceptive response to [D-Pen(2,5)]-enkephalin (DPDPE) is pharmacologically distinct from that to other delta-agonists in the rat. J Pharmacol Exp Ther 2000, 295:1135-1141.
34. Lohmann AB, Welch SP. Antisense to opioids receptors attenuate ATP-gated K+ channel opener-induced antinociception. Eur J Pharmacol 1999, 384:147-152. 10.1016/S0014-2999(99)00698-6, 10611434.
35. Pasternak GW, Standifer KM. Mapping of opioid receptors using antisense oligodeoxynucleotides: correlating their molecular biology and pharmacology. Trend Pharmacol Sci 1995, 16:344-350.
36. Gupta A, Décaillot FM, Gomes I, Tkalych O, Heimann AS, Ferro ES, Devi LA. Conformation state-sensitive antibodies to G-protein-coupled receptors. J Biol Chem 2007, 282:5116-5124. 10.1074/jbc.M609254200, 17148456.
37. Gupta A, Rozenfeld R, Gomes I, Raehal KM, Décaillot FM, Bohn LM, Devi LA. Post-activation-mediated changes in opioid receptors detected by N-terminal antibodies. J Biol Chem 2008, 283:10735-10744. 10.1074/jbc.M709454200, 2447646, 18256033.
38. El Kouhen R, Burd AL, Erickson-Herbrandson LJ, Chang CY, Law PY, Loh HH. Phosphorylation of Ser 363, Thr 370 and Ser 375 residues within the carboxyl tail differentially regulates μ-opioid receptor internalization. J Biol Chem 2001, 276:12774-12780. 10.1074/jbc.M009571200, 11278523.
39. Ferguson SS. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 2001, 53:1-24.
40. Whitman M, Downes CP, Keeler M, Keller T, Cantley L. Type I phosphatidylinositol kinase makes a novel inositol phospholipids phosphatidylinositol-3-phosphate. Nature 1988, 332:644-646. 10.1038/332644a0, 2833705.
41. Chan TO, Rittenhouse SE, Tsichlis PN. AKT/PKB and other D3 phosphoinositide-regulated kinases: activation by phosphoinositide-dependent phosphorylation. Annu Rev Biochem 1999, 68:965-914. 10.1146/annurev.biochem.68.1.965, 10872470.
42. Iglesias M, Segura MF, Comella JX, Olmos G. Mu-opioid receptor activation prevents apoptosis following serum withdrawal in differentiated SH-SY5Y cells and cortical neurons via phosphatidylinositol 3-kinase. Neuropharmacology 2003, 44:482-492. 10.1016/S0028-3908(03)00024-8, 12646285.
43. Gavi S, Shumay E, Wang H, Malbon CC. G-protein-coupled receptors and tyrosin kinases: crossroads in cell signalling and regulation. Trends Endocrinol Met 2006, 17:46-52.
44. Chen Y, Long H, Wu Z, Jiang X, Ma L. EGF transregulates opioid receptors through EGFR-mediated GRK2 phosphorylation and activation. Mol Biol Cell 2008, 19:2973-2983. 10.1091/mbc.E07-10-1058, 2441682, 18463167.
45. Al-Chaer ED, Kawasaki M, Pasricha PJ. A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development. Gastroenterology 2000, 119:1276-1285. 10.1053/gast.2000.19576, 11054385.
46. Ness TJ, Gebhart GF. Visceral pain: a review of experimental studies. Pain 1990, 41:167-234. 10.1016/0304-3959(90)90021-5, 2195438.
47. Calcagnetti DJ, Holtzman SG. Delta Opioid antagonist naltrindole, selectively blocks analgesia induced by DPDPE but not DAMGO or morphine. Pharmacol Biochem Behav 1991, 38:185-190. 10.1016/0091-3057(91)90608-5, 2017444.
48. Jewett DC, Grace MK, Jones RM, Billington CJ, Portoghese PS, Levine AS. The kappa-opioid antagonist GNTI reduces U50,488-, DAMGO-, and deprivation-induced feeding but not butorphanol- and neuropeptide Y-induced feeding in rats. Brain Res 2001, 909:75-80. 10.1016/S0006-8993(01)02624-5, 11478923.
49. Sterious SN, Walker EA. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay. J Pharmacol Exp Ther 2003, 304:301-309. 10.1124/jpet.102.042093, 12490605.
50. Rossi GC, Pan Y-X, Brown GP, Pasternak GW. Antisense mapping the MOR-1 opioid receptor: evidence of alternative splicing and a novel morphine-6β-glucuronide receptor. FEBS Letters 1995, 369:192-196. 10.1016/0014-5793(95)00757-Z, 7649256.
51. Rossi GC, Leventhal L, Pan YX, Cole J, Su W, Bodnar RJ, Pasternak GW. Antisense mapping of MOR-1 in rats: distinguishing between morphine and morphine-6β-glucoronide antinociception. J Pharmacol Exp Ther 1997, 281:109-114.
52. Silva RM, Grossman HC, Hadjimarkou MM, Rossi GC, Pasternak GW, Bodnar RJ. Dynorphin A1-17--induced feeding: pharmacological characterization using selective opioid antagonists and antisense probes in rats. J Pharmacol Exp Ther 2002, 301:513-518. 10.1124/jpet.301.2.513, 11961051.
53. Israel Y, Kandov Y, Khaimova E, Kest A, Lewis SR, Pasternak GW, Pan YX, Rossi GC, Bodnar RJ. NPY-induced feeding: pharmacological characterization using selective opioid antagonists and antisense probes in rats. Peptides 2005, 26:1167-1175. 10.1016/j.peptides.2005.01.017, 15949635.
54. Bonaz B, Rivière PJ, Sinniger V, Pascaud X, Junien JL, Fournet J, Feuerstein C. Fedotozine, a kappa-opioid agonist prevents spinal and supra-spinal Fos expression induced by a noxious visceral stimulus in the rat. Neurogastroenterol Motil 2000, 2:135-147.
55. Gomes I, Gupta A, Singh SP, Sharma SK. Monoclonal antibody to the delta opioid receptor acts as an agonist in dual regulation of adenylate cyclase in NG 108-15 cells. FEBS Lett 1999, 456:126-130. 10.1016/S0014-5793(99)00878-9, 10452543.